May 24, 2022 / 12:30PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Good morning, everyone. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thank you, everyone, for joining us for day 2 of the UBS Global Healthcare Conference in person. Very happy to have Madrigal Pharmaceuticals here with us for a fireside chat this morning.
Joining us from Madrigal are Paul Friedman, Chairman and Chief Executive Officer; Alex Howarth, Chief Financial Officer; and Rebecca Taub, Founder, CMO and President of R&D; and Remy Sukhija, Chief Commercial Officer, who may be in the audience here for some Q&A. And with that, I thank you guys so much for joining us.
Questions and Answers:
Eliana Rachel Merle - UBS Investment Bank, Research Division - AnalystAnd maybe just to kick it off, can you tell us sort of high level some sort of background on the company? Where you are? And it's certainly been an eventful past couple of years and an eventful year to come. And sort of frame for us all the important milestones that we should be looking out for
Trustpilot
